Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

1.150 +0.040 (+3.60%)
Official Closing Price Updated: 4:15 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,985,830
Open 1.130
Bid (Size) 1.160 (19)
Ask (Size) 1.180 (1)
Prev. Close 1.110
Today's Range 1.100 - 1.160
52wk Range 1.065 - 6.420
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 212 companies made new 52-week lows. 
Via Benzinga
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire

Performance

YTD
-63.38%
-63.38%
1 Month
-13.53%
-13.53%
3 Month
-59.65%
-59.65%
6 Month
-68.49%
-68.49%
1 Year
-68.66%
-68.66%

More News

Read More
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
From Sangamo Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics's Return On Capital Employed Overview
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Soon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major Restructuring
Via Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
Via InvestorPlace
Boeing, Spirit AeroSystems And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Via InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Via Benzinga
UBS Group, Credit Suisse And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
10 Companies That Had Tons of Money in SVB When It Collapsed
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.